CLEC12A

Across TCGA pan-cancer cohorts, CLEC12A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC12A data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLEC12A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC12A expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where CLEC12A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.137	0.779	.038	6	view →
GBM	DFS	Median	All	0.443	0.169	.020	4	view →
LUAD	DFS	Median	II,III,IV	0.791	0.456	.028	3	view →
HNSC	DFS	Quartile	III,IV	0.464	0.947	.012	3	view →
LSCC	DFS	Quartile	III,IV	1.000	0.660	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC12A–PDAC (DFS)

Open the PDAC breakdown →